Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 47 results for "Indolent B-Cell Lymphoma (IBCL)".

Thumbnail for Long-Term Follow-Up From the Rituximab Era Describes a Substantial "One-and-Done" Population After Frontline Treatment for Follicular Lymphoma

IBCL - 1072

Long-Term Follow-Up From the Rituximab Era Describes a Substantial "One-and-Done" Population After Frontline Treatment for Follicular Lymphoma

Jonathan Day

Poster Presenter: Jonathan Day

Thumbnail for Outcomes of Hairy Cell Leukemia in Resource-Constrained Settings: A Retrospective Single-Center Study From Pakistan

IBCL - 1143

Outcomes of Hairy Cell Leukemia in Resource-Constrained Settings: A Retrospective Single-Center Study From Pakistan

Khadija Bano

Poster Presenter: Khadija Bano

Previous 1 2 3 4 5 6 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Risk Stratification of Acute Kidney Injury in Waldenstrφm Macroglobulinemia: Machine Learning-Derived Clinical Phenotypes From a National Inpatient Database

IBCL - 1171

Risk Stratification of Acute Kidney Injury in Waldenstrφm Macroglobulinemia: Machine Learning-Derived Clinical Phenotypes From a National Inpatient Database

Krupa Savani

Poster Presenter: Krupa Savani

Thumbnail for Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenstrφm Macroglobulinemia: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies

IBCL - 1172

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenstrφm Macroglobulinemia: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies

Shiwani Keswani

Poster Presenter: Shiwani Keswani

Thumbnail for Rosai-Dorfman disease, histiocytosis, radiotherapy, rare diseases, real-world data

IBCL - 1262

Rosai-Dorfman disease, histiocytosis, radiotherapy, rare diseases, real-world data

Janeth Araujo Cardenas

Poster Presenter: Janeth Araujo Cardenas

Thumbnail for Trends in Non-Hodgkin Lymphoma Incidence, Mortality, and Disease Burden Across Latin America from 1990 to 2023: A Global Burden of Disease Study

IBCL - 1325

Trends in Non-Hodgkin Lymphoma Incidence, Mortality, and Disease Burden Across Latin America from 1990 to 2023: A Global Burden of Disease Study

Renusri Ede

Poster Presenter: Renusri Ede

$Thumbnail for Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab (E) With Lenalidomide and Rituximab (R2) versus R2 for Relapsed or Refractory Follicular Lymphoma (R/R FL)$

IBCL - 1332

Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab (E) With Lenalidomide and Rituximab (R2) versus R2 for Relapsed or Refractory Follicular Lymphoma (R/R FL)

Bradley D. Hunter*

Poster Presenter: Bradley D. Hunter*

Thumbnail for Epidemiology and Hospital Utilization in Peripheral T-Cell Lymphoma: A Retrospective Study From National Inpatient Sample 2023

IBCL - 1337

Epidemiology and Hospital Utilization in Peripheral T-Cell Lymphoma: A Retrospective Study From National Inpatient Sample 2023

Namitha Thotli

Poster Presenter: Namitha Thotli

$Thumbnail for Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab (E+R2) in EPCORE FL-1 vs Real-World Chemoimmunotherapy (CIT) in Relapsed/Refractory Follicular Lymphoma (R/R FL)$

IBCL - 1346

Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab (E+R2) in EPCORE FL-1 vs Real-World Chemoimmunotherapy (CIT) in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Habte Yimer

Poster Presenter: Habte Yimer

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors